Drugs / CGT4255
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07361562 | Dec 2025 → May 2028 expected | breast cancer, non-small cell lung carcinoma | Cogent Biosciences, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CGT4255 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07361562 ↗ |
| Action | Inhibit | “A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors” NCT07361562 ↗ |
| Route | Oral | “CGT4255 Daily Oral Administration” NCT07361562 ↗ |
| Target | ERBB2 | “A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors” NCT07361562 ↗ |